SCI
VRTX icon

S&CO Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

S&CO Inc’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04M Hold
4,103
– – 0.12% 116
2026
Q1 		$1.83M Hold
4,103
– – 0.11% 116
2025
Q4 		$1.86M Hold
4,103
– – 0.12% 118
2025
Q3 		$1.61M Hold
4,103
– – 0.1% 122
2025
Q2 		$1.83M Hold
4,103
– – 0.12% 120
2025
Q1 		$1.99M Buy
+4,103
New +$1.91M 0.13% 113

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

S&CO Inc's VRTX Position: Q2 2026 in Review

S&CO Inc held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 4,103 shares worth $2.04M. The position accounts for 0.12% of the portfolio, ranked #116.

S&CO Inc first reported a position in VRTX in Q1 2025 and has held it in 6 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • S&CO Inc held 4,103 shares of Vertex Pharmaceuticals worth $2.04M as of Q2 2026.
  • S&CO Inc left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.12% of S&CO Inc's portfolio in Q2 2026, its #116 holding.
  • S&CO Inc first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on S&CO Inc's 13F filing for Q2 2026, filed 6 Aug 2026.